GWAS Research of Lung Cancer in Tianjin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Tianjin Medical University Cancer Institute and Hospital.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital Identifier:
First received: December 5, 2010
Last updated: July 31, 2014
Last verified: January 2012

To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

Non-small Cell Lung Cancer
Primary Carcinoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: GWAS Research of Lung Cancer by Department of Epidemiology and Biostatistics in Tianjin Medical University Cancer Institute and Hospital

Resource links provided by NLM:

Further study details as provided by Tianjin Medical University Cancer Institute and Hospital:

Primary Outcome Measures:
  • Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia [ Time Frame: 2011-12 ] [ Designated as safety issue: Yes ]
    A GWAS reported a novel association between the TP63 locus and risk of lung adenocarcinoma; however, this association did not achieve genome-wide significance among never-smoking males or females. We genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 500 never-smoking female lung cancer cases and 500 never-smoking female controls from China. Genetic variation in rs10937405 was associated with lung adenocarcinoma. Our findings provide strong evidence that genetic variation in TP63 is associated with risk of lung adenocarcinoma among non-smoking females.

Biospecimen Retention:   Samples With DNA

Peripheral blood sample (10 ml) was collected from each study subject. Buffy coats were isolated and frozen for DNA extraction.

Estimated Enrollment: 500
Study Start Date: June 2010
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Female lung cancer group
Female, non-smoker, non-small cell lung cancer
Health control
Female, non-smokers, no lung cancer or other types of cancers` healthy population

Detailed Description:

Eligibility criteria:

  • nonsmoker
  • female
  • age between 35 and 80
  • no other types of tumors history
  • frequency-matched cases and controls on gender and age

Outcome measures:

  • OR(odds ratio)
  • RR(risk ratio)
  • CI(confidence interval)
  • SAS software

Ages Eligible for Study:   35 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients were newly diagnosed and histologically confirmed primary non-small cell lung cancer from Tianjin Medical University Cancer Hospital.The control subjects who underwent health check-up in hospitals were frequency-matched to cases on gender and age. All the subjects were genetically unrelated Chinese with Han ethnicity.


Inclusion Criteria:

  • Non-small cell lung cancer
  • Age from 35 to 80 years old
  • Female
  • Non-smokers
  • Frequency-matched on age and gender

Exclusion Criteria:

  • Previous medical history of cancer
  • Previous radiotherapy
  • Previous chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01255059

Contact: Chen Kexin, M.D., Ph.D 0086-022-23372231

China, Tianjin
Tianjin Medical University Cancer Institute and Hospital Recruiting
Tianjin, Tianjin, China, 300060
Contact: Chen Kexin, M.D., Ph.D    0086-022-23372231   
Principal Investigator: Chen Kexin, M.D., Ph.D         
Sponsors and Collaborators
Tianjin Medical University Cancer Institute and Hospital
Study Director: Chen Kexin, M.D., Ph.D Tianjin Medical University Cancer Institute and Hospital
  More Information

Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, Mirabello L, Jacobs K, Wheeler W, Yeager M, Bergen AW, Li Q, Consonni D, Pesatori AC, Wacholder S, Thun M, Diver R, Oken M, Virtamo J, Albanes D, Wang Z, Burdette L, Doheny KF, Pugh EW, Laurie C, Brennan P, Hung R, Gaborieau V, McKay JD, Lathrop M, McLaughlin J, Wang Y, Tsao MS, Spitz MR, Wang Y, Krokan H, Vatten L, Skorpen F, Arnesen E, Benhamou S, Bouchard C, Metspalu A, Vooder T, Nelis M, Välk K, Field JK, Chen C, Goodman G, Sulem P, Thorleifsson G, Rafnar T, Eisen T, Sauter W, Rosenberger A, Bickeböller H, Risch A, Chang-Claude J, Wichmann HE, Stefansson K, Houlston R, Amos CI, Fraumeni JF Jr, Savage SA, Bertazzi PA, Tucker MA, Chanock S, Caporaso NE. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009 Nov;85(5):679-91. doi: 10.1016/j.ajhg.2009.09.012. Epub 2009 Oct 15. Erratum in: Am J Hum Genet. 2011 Jun 10;88(6):861. Metsapalu, Andres [corrected to Metspalu, Andres].

Responsible Party: Tianjin Medical University Cancer Institute and Hospital Identifier: NCT01255059     History of Changes
Other Study ID Numbers: TMU-CIH-GWASLC-Epi-Tianjin
Study First Received: December 5, 2010
Last Updated: July 31, 2014
Health Authority: China: Ethics Committee

Keywords provided by Tianjin Medical University Cancer Institute and Hospital:
Genome-wide association studies(GWAS)
Single nucleotide polymorphism(SNP)
Lung cancer processed this record on March 26, 2015